Glucagon-like peptide-1 receptor agonists in diabetic patients with heart failure with reduced ejection fraction - real world outcomes

In a real-world cohort of 7,878 diabetic adults with HFrEF, GLP-1 receptor agonist use after HF diagnosis is linked to lower risk of heart failure hospitalization or death (RR 0.58 at 12 months).

• Why it matters: People with diabetes and HFrEF face high rates of hospitalization and death, and evidence on GLP-1 receptor agonists’ clinical outcomes in routine care remains needed.
• What they did: Adults with diabetes mellitus and HFrEF (2014–2025) were studied in a retrospective observational cohort; 793 GLP-1 RA initiators were matched to 1,825 controls using stratified exact matching, with bootstrap (1,000 iterations) and Cox time-to-event validation.
• The result: GLP-1 RA therapy was associated with reduced risk at 12 months (RR 0.58, 95% CI 0.42–0.77) and 36 months (RR 0.72, 95% CI 0.61–0.85), yielding NNTs of 17 at 1 year and 13 at 3 years.

AI summary of the abstract · may contain errors · not medical advice · read the paper.